# CSPC Megalith Biopharmaceutical Co.,Ltd. trials: 42 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 42 trials with CSPC Megalith Biopharmaceutical Co.,Ltd. as lead sponsor, 41 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by CSPC Megalith Biopharmaceutical Co.,Ltd.: 42 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/cspc-megalith-biopharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 42
- Recruiting or not yet: 41
- Read on: November 19, 2026

## Trials

The 25 newest of 42, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07925775 | Immunogenicity and Safety of SYS6057 in the Participants Aged 18 Years and Above | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1 | Not yet recruiting | Lower Respiratory Tract Disease Caused by RSV Infection | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925775) |
| November 9, 2026 | NCT07925021 | A Study of SYS6010 Combined With Enlonstobart in Patients With Previously Systemic Treatment-Naive R/M Nasopharyngeal Carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Recruiting | Previously Systemic Treatment-Naive Recurrent or Metastatic Nasopharyngeal Carcinoma | 424 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925021) |
| November 9, 2026 | NCT07924111 | A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or... | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Not yet recruiting | Esophageal Squamous Cell Carcinoma | 585 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924111) |
| October 27, 2026 | NCT07897227 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SYS6062 in Patients With Advanced Solid Tumors. | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors, Gastric Cancer (GC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC) | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897227) |
| October 23, 2026 | NCT07892989 | Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and Above | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1/2 | Not yet recruiting | Herpes Zoster | 496 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892989) |
| October 19, 2026 | NCT07879911 | A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or... | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Not yet recruiting | Triple Negative Breast Cancer | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07879911) |
| October 5, 2026 | NCT07857135 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1/2 | Not yet recruiting | Advanced/Metastatic Solid Tumors | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857135) |
| September 22, 2026 | NCT07833735 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of SYS6043 ± Bevacizumab ± Chemotherapy in... | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07833735) |
| August 20, 2026 | NCT07776041 | A Study of SYH2092 Injection in Healthy Participants | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1 | Not yet recruiting | Overweight or Obesity | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07776041) |
| August 12, 2026 | NCT07761286 | Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1/2 | Not yet recruiting | HCC - Hepatocellular Carcinoma | 288 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07761286) |
| August 11, 2026 | NCT07758621 | SYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurrent or Metastatic HNSCC | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Not yet recruiting | Head and Neck Squamous Cell Carcinoma | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07758621) |
| August 6, 2026 | NCT07750041 | A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1/2 | Not yet recruiting | Unresectable Advanced or Metastatic Colorectal Cancer | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07750041) |
| August 4, 2026 | NCT07744763 | A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1/2 | Recruiting | Advanced Solid Tumors | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07744763) |
| July 20, 2026 | NCT07714668 | A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 2 | Recruiting | Ovarian Cancer, Recurrent Ovarian Cancer | 171 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07714668) |
| July 16, 2026 | NCT07708753 | A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Recruiting | Platinum-resistant Ovarian Cancer, Platinum-resistant Primary Peritoneal Cancer, Platinum-resistant Fallopian Tube... | 460 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07708753) |
| July 14, 2026 | NCT07702656 | A Phase II Clinical Trial Evaluating the Efficacy and Safety of SYS6026 Injection in Participants With HPV16 or 18-related High-grade... | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 2 | Not yet recruiting | High-grade Cervical Intraepithelial Lesions | 175 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07702656) |
| July 6, 2026 | NCT07684261 | A Multicenter, Open-label, Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics (PK), and... | CSPC Megalith Biopharmaceutical Co.,Ltd. | Observational | Not yet recruiting | Solid Tumor | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684261) |
| June 26, 2026 | NCT07672223 | A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC) | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Recruiting | Non-small Cell Lung Cancer | 586 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07672223) |
| June 8, 2026 | NCT07633873 | SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or... | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Not yet recruiting | Non-Small Cell Lung Cancer | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07633873) |
| June 3, 2026 | NCT07622225 | SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid Tumors | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors | 264 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07622225) |
| May 19, 2026 | NCT07597629 | A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 2 | Recruiting | Advanced Breast Cancer | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07597629) |
| May 15, 2026 | NCT07591285 | A Study of SYS6051 in Subjects With Advanced Solid Tumors | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1 | Not yet recruiting | Advanced Solid Tumors | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07591285) |
| April 13, 2026 | NCT07526792 | SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Not yet recruiting | Urothelial Carcinoma | 406 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07526792) |
| March 2, 2026 | NCT07442565 | SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Not yet recruiting | Non-Small Cell Lung Cancer | 506 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07442565) |
| February 18, 2026 | NCT07417735 | SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Not yet recruiting | Locally Advanced/Metastatic/Recurrent ESCC | 436 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07417735) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 7 |
| Phase 1/2 | 11 |
| Phase 2 | 8 |
| Phase 2/3 | 1 |
| Phase 3 | 14 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Not yet recruiting | 29 |
| Recruiting | 12 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 5 |
| Herpes Zoster | 3 |
| Squamous Cell Carcinoma of Head and Neck | 3 |
| Breast Neoplasms | 2 |
| Esophageal Squamous Cell Carcinoma | 2 |
| Colorectal Neoplasms | 2 |
| Nasopharyngeal Carcinoma | 1 |
| Ovarian Neoplasms | 1 |
| Carcinoma, Transitional Cell | 1 |
| Carcinoma, Hepatocellular | 1 |
| Overweight | 1 |
| Obesity | 1 |
| Recurrence | 1 |
| Stomach Neoplasms | 1 |
| Small Cell Lung Carcinoma | 1 |
| Uterine Cervical Neoplasms | 1 |
| Triple Negative Breast Neoplasms | 1 |
| Parkinson Disease 4, Autosomal Dominant Lewy Body | 1 |
| Diabetes Mellitus, Insulin-Dependent, 12 | 1 |
| Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Occupational medicine clinics in the United States](https://specstream.ai/data/businesses/occupational-medicine-clinics/united-states)
- [Art schools in the United States](https://specstream.ai/data/businesses/art-schools/united-states)
- [Hawaiian restaurants in the United States](https://specstream.ai/data/businesses/hawaiian-restaurants/united-states)
- [Soup restaurants in the United States](https://specstream.ai/data/businesses/soup-restaurants/united-states)
- [Cooking schools in the United States](https://specstream.ai/data/businesses/cooking-schools/united-states)
- [Nursing schools in the United States](https://specstream.ai/data/businesses/nursing-schools/united-states)
